RxDoctor Payments Data

Chad McRee, MD

Interventional Cardiology · Concord, NCNPI 1124385927

Payments from drug & device makers

$25,166in general payments, 2019–2025

Across 141 payments — averaging $178.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$20K
  • Edwards Lifesciences$2K
  • Boston Scientific$1K
  • Abiomed$745
  • Abbott$429
  • Novartis$308
  • plus $999 from 15 others
$108in research payments, 2019–2025

Across 1 payment — averaging $108.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$108

What the payments were for

  • Consulting fees$1,2005%
  • Grants$18,00072%
  • Travel & lodging$1,7017%
  • Food & beverage$4,26617%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,166 in reported general payments places this provider in the 60th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$152,177
Medicare patients
386
Services billed
1,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban139$114,964
Repatha SureclickEvolocumab71$72,054
EntrestoSacubitril/Valsartan77$71,210
XareltoRivaroxaban33$25,968
FarxigaDapagliflozin Propanediol21$15,357
VascepaIcosapent Ethyl13$7,270
NexletolBempedoic Acid11$5,147
NexlizetBempedoic Acid/Ezetimibe12$4,626
Atorvastatin Calcium265$2,402
Ranolazine ErRanolazine32$1,947
ClopidogrelClopidogrel Bisulfate231$1,926
Metoprolol Succinate153$1,376
Furosemide213$1,088
Losartan Potassium77$979
Rosuvastatin Calcium58$709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$114,964139 claims
NovartisEntresto$308$71,21077 claims
Johnson & JohnsonXarelto$271$25,96833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Concord

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →